Speaker Profile

M.D., Co-Director, Breast and Ovarian Cancer Genetics and Risk Assessment, Massachusetts General Hospital; Associate Professor of Surgery, Harvard Medical School; Medical Director, Cancer Genetics and Risk Assessment, Hamilton, Bermuda

Dr. Hughes is actively involved in research regarding the genetics, screening, diagnosis and treatment of breast cancer and is actively involved in the development of Health Information Technology that improves quality while decreasing clinician workload. He co-authored the HL7, ANSI approved standard for transmitting family health history, and was the Principal Investigator for the Cooperative Group Trial (CALGB 9343) that showed radiation therapy had little benefit in women over age 70 with early breast cancer.

Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: Despite the impressive advances in precision medicine, none have been effectively implemented in standard medical practice. Within the realm of genetics, hereditary cancer testing was one of the earliest advances and is now poised to be the first to achieve proper adoption. We will discuss the barriers to adoption, why it will be important to implement broader screening, and what this means for the adoption of precision medicine more generally.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.